Brought to you by:
Shockwave IVL maintains ‘superiority’ to angioplasty in calcified peripheral disease at two years
Shockwave Medical announced today that long-term data from the Disrupt PAD III trial found that superior vessel preparation with intravascular lithotripsy (IVL) led to excellent long-term outcomes out to two years with preservation of future treatment options compared to percutaneous transluminal angioplasty (PTA)…
Tissue samples show paclitaxel effect in minority of CLTI patients receiving DCB angioplasty, study finds
Paclitaxel effect was witnessed in tissue specimens of a minority of chronic limb-threatening ischemia (CLTI) patients treated with drug-coated balloons (DCBs)—but was not dependent on DCB type, nor the dose level of the drug administered, and was not associated with…
The top 10 most popular Vascular Specialist stories in March
Among the posts catching Vascular Specialist readers’ eyes last month were the digital flipbook version of our March print edition, a new study looking at the Society for Vascular Surgery (SVS) open abdominal aortic aneurysm (AAA) recommendations, and an interview…
Alucent Biomedical announces first patient enrolled in first-in-human natural vascular scaffolding clinical trial
Alucent Biomedical announced in a press release that it has enrolled the first patient in ACTIVATE II, an Australia-based first-in-human clinical trial to evaluate the safety and efficacy of its natural vascular scaffolding (AlucentNVS) technology. The therapy is designed to open…
Shockwave Medical announces global launch of new peripheral IVL catheter
Shockwave Medical has announced the global commercial availability of the Shockwave M5+ peripheral intravascular lithotripsy (IVL) catheter after receiving both Food and Drug Administration (FDA) and CE mark clearance. A company press release details that the Shockwave M5+ catheter is specifically designed to…
SCVS 2022: WIfI score does not predict successful healing after transmetatarsal amputation, study finds
A higher initial Wound, ischemia, and foot infection (WIfI) classification score at initial presentation in chronic limb-threatening ischemia (CLTI) patients who underwent a transmetatarsal amputation (TMA) was not associated with a major amputation down the road, according to a retrospective…
Potential ‘new paradigm’ in treatment of long occlusive lesions emerges
Vascular surgeon Lewis Schwartz, MD, has had an interest in biomedical engineering since very early in his career. So his involvement in the early-stage Efemoral vascular scaffold system marks a significant milestone in a mission to save legs and provide…
PROMISE II U.S. pivotal trial of device designed for ‘no-option’ CLTI patients completes enrollment
Enrollment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialization system designed to prevent amputations in so-called “no-option” chronic limb-threatening ischemia (CLTI) patients, the eponymous device maker announced today. “The PROMISE II investigators are…
Viabahn use in claudicants with long, complex SFA lesions ‘safe and effective’ through five years
Recently published research indicates that stent grafting with the Viabahn endoprosthesis (W L Gore & Associates) of long and complex superficial femoral artery (SFA) lesions in patients with claudication is a safe and effective long-term treatment option. Writing in the Journal of Vascular…
Ra Medical Systems receives FDA approval for increased enrollment in atherectomy clinical trial
Ra Medical Systems, a medical device company focused on developing the excimer laser system to treat vascular diseases, has announced that enrollment has reached 95 subjects in the pivotal clinical trial to evaluate the safety and effectiveness of the DABRA…